Extramedullary plasmacytoma in the presence of multiple myeloma: Clinical correlates and prognostic relevance

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 329-334

  Chen, Hai Fei ^a   Wu, Tian Qin ^a   Li, Zheng Yang ^a   Shen, Hong Shi ^a   Fu, Wei Jun ^b   Yuan, Zhen Gang ^b   Hou, Jian ^b  

^a Medical Centre of Hematologic and Oncologic Diseases of Nanjing Military Command   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Extramedullary multiple myeloma; Plasmacytoma

Indexed keywords

ALBUMIN; ALKYLATING AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; C REACTIVE PROTEIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL MATURATION; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MONOTHERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA CELL; PLASMACYTOMA; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 84873904996     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S35348     Document Type: Article

References (27)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91(1): 3-21.
2. Oriol A. Multiple myeloma with extramedullary disease. Adv Ther. 2011;28 Suppl 7:1-6.
3. Uppal HS, Harrison P. Extramedullary plasmacytoma of the larynx presenting with upper airway obstruction in a patient with long-standing IgD myeloma. J Laryngol Otol. 2001;115(9):745-746.
4. Chetty R, Bramdev A, Reddy AD. Primary extramedullary plasmacytoma of the esophagus. Ann Diagn Pathol. 2003;7(3):174-179.
5. Chim CS, Wong WM, Nicholls J, Chung L P, Liang R. Extramedullary sites of involvement in hematologic malignancies: case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma. J Clin Oncol. 2002;20(1):344-347.
6. Kintzer JS Jr, Rosenow EC 3rd, Kyle RA. Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med. 1978;138(5):727-730.
7. Fernandez LA, Couban S, Sy R, Miller R. An unusual presentation of extramedullary plasmacytoma occurring sequentially in the testis, subcutaneous tissue, and heart. Am J Hematol. 2001;67(3):194-196.
8. Giuliani N, Caramatti C, Roti G, et al. Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes. J Clin Oncol. 2003;21(9):1887-1888.
9. Green T, Grant J, Pye R, Marcus R. Multiple primary cutaneous plasmacytomas. Arch Dermatol. 1992;128(7):962-965.
10. Rosenblum MD, Bredeson CN, Chang CC, Rizzo JD. Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant. Am J Hematol. 2003;72(4):274-277.
11. Alegre A, Martinez-Chamorro C, Fernandez-Ranada JM. Massive myelomatous ascites responsive to VA D chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 1999;24(3): 343-344.
12. Petrucci MT, Tirindelli MC, De Muro M, Martini V, Levi A, Mandelli F. Extramedullary liver plasmacytoma a rare presentation. Leuk Lymphoma. 2003;44(6):1075-1076.
13. Fujikata S, Tanji N, Aoki K, Ohoka H, Hojo N, Yokoyama M. Extramedullary plasmacytoma arising from an adrenal gland. Urology. 2002;60(3):514.
14. Menke DM, Horny H P, Griesser H, et al. Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol. 2001;115(1): 119-126.
15. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117(1):103-108.
16. International Myeloma Working Group. Criteria for the classifcation of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
17. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115-1123.
18. Dinse GE, Lagakos S W. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics. 1982;38(4):921-932.
19. Cox DR. Regression models and life-tables. J Roy Stat Soc B. 1972;34(2): 187-220.
20. Fassas ABT, Ward S, Muwalla F, et al. Myeloma of the central nervous system: Strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45(2):291-300.
21. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(3):1032-1037.
22. Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma-cell leukaemia. Br J Haematol. 1994;88(4):754-759.
23. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med. 1975;135(1):87-93.
24. Damaj G, Mohty M, Vey N, et al. Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. Eur J Haematol. 2004;73(6):402-406.
25. Ali R, Ozkalemkas F, Ozkan A, et al. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res. 2007;31(8):1153-1155.
26. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513.
27. Bold R. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, PhD, and Michael Kauffman, MD, PhD. Cancer Invest. 2004;22(2):304-311.